We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration Collaboration partner to use AI and machine learning...
A Maryland-based biotech company found very early success during Tuesday’s premarket hours a day after the company reported statistically significant phase 2a results for To read the full...
Based on successful Phase 2a data, Company set to initiate Phase 2b sarcopenia study in early 2025; currently securing centers of excellence to begin enrollment First oral TNF-α inhibitor, if...
Prevail Partners, LLC investment priced at more than a 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.18 | 15 | 1.2 | 1.58 | 1.05 | 281713 | 1.37126692 | CS |
4 | -0.01 | -0.719424460432 | 1.39 | 1.64 | 1.05 | 238053 | 1.40377782 | CS |
12 | -0.31 | -18.3431952663 | 1.69 | 1.95 | 1.05 | 104138 | 1.43659093 | CS |
26 | -0.62 | -31 | 2 | 2.16 | 1.05 | 80102 | 1.53977271 | CS |
52 | -0.62 | -31 | 2 | 2.16 | 1.05 | 80102 | 1.53977271 | CS |
156 | -0.62 | -31 | 2 | 2.16 | 1.05 | 80102 | 1.53977271 | CS |
260 | -0.62 | -31 | 2 | 2.16 | 1.05 | 80102 | 1.53977271 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions